Kraig Biocraft Laboratories Reports Increased Net Loss and Rising Operating Expenses in Q2 2026

Kraig Biocraft Laboratories, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $909,535, a 25.3% increase from the $726,133 loss recorded in the same period of 2025. The company did not generate any revenue during the quarter, consistent with the previous year. Total operating expenses rose to $703,433, up from $637,745, driven primarily by increases in general and administrative costs, professional fees, and officer salaries. General and administrative expenses alone increased by 8.8% to $374,381, while professional fees surged by 60.1% to $69,862.

For the first half of 2026, Kraig Biocraft reported a net loss of $1,852,255, a 39.7% increase compared to the $1,326,166 loss in the first half of 2025. Total operating expenses for this period reached $1,528,933, up from $1,218,237, with significant contributions from research and development expenses, which increased by 49.3% to $131,070. The company’s cash and cash equivalents improved to $3,391,646 as of June 30, 2026, compared to $1,790,236 at the end of 2025, reflecting a net cash inflow from financing activities of $2,772,547 during the first half of the year.

Kraig Biocraft's total assets increased to $4,271,792 from $2,565,540 at the end of 2025, primarily due to a rise in cash and inventory levels. The company’s inventory grew significantly to $134,142 from $29,067, indicating a strategic buildup of resources for future production. However, total liabilities also increased to $11,022,908 from $10,564,498, with current liabilities rising to $10,901,744, reflecting ongoing financial obligations, particularly to related parties.

The company continues to focus on its strategic initiatives, including the expansion of its recombinant spider silk production and research efforts. Kraig Biocraft is also exploring potential acquisitions to enhance its operational capabilities and financial stability. Despite the current financial challenges, management remains optimistic about securing additional funding and achieving sustainable revenue growth in the future. The company has acknowledged the substantial doubt about its ability to continue as a going concern, emphasizing the need for further capital to support its business objectives.